Capricor’s peer-reviewed publication in Biomedicines reinforced the scientific foundation of its Duchenne therapy Deramiocel, ...

Publication highlights Deramiocel’s anti-fibrotic activity and describes a validated potency assay supporting quality control ...

Capricor Therapeutics (CAPR) announced the publication in Biomedicines, an international peer-reviewed journal, describing a novel in-vitro ...

Capricor Therapeutics (NASDAQ: CAPR) is a biotechnology company dedicated to advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. At the ...

Capricor Therapeutics finds itself navigating turbulent waters as a federal securities class action lawsuit casts uncertainty over the company's future. The legal investigation, made public on October ...

FDA and Capricor aligned on endpoints for HOPE-3 pivotal trial HOPE-3 pivotal trial completed; topline data expected mid-Q4 2025 to support BLA resubmission Company preparing to resubmit CRL response ...

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Capricor Therapeutics, Inc. (“Capricor” or the ...

Capricor Therapeutics said the U.S. Food and Drug Administration has rejected its application seeking approval of its lead cell-therapy candidate Deramiocel in the neuromuscular genetic disease ...

FDA issued Complete Response Letter Capricor plans to resubmit its BLA to include data from the ongoing Phase 3 HOPE-3 trial in Q3 2025 to continue pursuing the indication for the treatment of ...

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. The Food and Drug Administration has rejected what was ...

FDA has indicated that an Advisory Committee meeting is not required at this time In-person late-cycle review meeting scheduled for mid-July Biologics License Application (BLA) remains under Priority ...